Tetraphase Pharmaceuticals to Present Antibiotics Pipeline Data at ASM Microbe 2017
May 22, 2017 08:00 ET
|
Tetraphase Pharmaceuticals
Eleven Abstracts Selected for Presentation, Including Four Highlighting Pharmacokinetic and Global Surveillance Data for Eravacycline TP-6076 Phase 1 Single-Ascending Dose Data Selected for Oral...
Tetraphase Pharmaceuticals Reports First Quarter 2017 Financial Results and Reviews Recent Highlights
May 04, 2017 16:05 ET
|
Tetraphase Pharmaceuticals
WATERTOWN, Mass., May 04, 2017 (GLOBE NEWSWIRE) -- Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a clinical-stage biopharmaceutical company developing novel antibiotics to treat life-threatening...
Tetraphase Pharmaceuticals to Present Data at 27th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)
April 21, 2017 08:00 ET
|
Tetraphase Pharmaceuticals
WATERTOWN, Mass., April 21, 2017 (GLOBE NEWSWIRE) -- Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a clinical stage biopharmaceutical company developing novel antibiotics to treat life-threatening...
Tetraphase Pharmaceuticals Completes Enrollment of IGNITE4 Phase 3 Clinical Trial of Eravacycline in Complicated Intra-abdominal Infections
April 03, 2017 08:00 ET
|
Tetraphase Pharmaceuticals
Accelerated Timelines for Both Top-line IGNITE4 Eravacycline Data and MAA filing in Europe; Both Now Expected in 3Q 2017 IGNITE4 Results to Support U.S. NDA Filing for IV...
Tetraphase Pharmaceuticals’ TP-6076 Selected by CARB-X to Receive $4 Million in Research Funding
March 30, 2017 16:01 ET
|
Tetraphase Pharmaceuticals
WATERTOWN, Mass., March 30, 2017 (GLOBE NEWSWIRE) -- Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a clinical stage biopharmaceutical company developing novel antibiotics to treat life-threatening...
Tetraphase Pharmaceuticals to Present at the 16th Annual Needham Healthcare Conference
March 27, 2017 08:00 ET
|
Tetraphase Pharmaceuticals
WATERTOWN, Mass., March 27, 2017 (GLOBE NEWSWIRE) -- Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) a clinical stage biopharmaceutical company developing novel antibiotics to treat life-threatening...
Tetraphase Pharmaceuticals Reports Fourth Quarter and Full-Year 2016 Financial Results and Highlights Key 2017 Milestones
March 08, 2017 16:05 ET
|
Tetraphase Pharmaceuticals
–Event-Driven 2017 Includes MAA Filing for IV Eravacycline in Europe and Top-Line Data Readout from IGNITE4 in cIAI – – Company to Host Conference Call Today, March 8, 2017 at 4:30 p.m. ET – ...
Tetraphase Pharmaceuticals to Present at the 29th Annual ROTH Conference
March 06, 2017 08:00 ET
|
Tetraphase Pharmaceuticals
WATERTOWN, Mass., March 06, 2017 (GLOBE NEWSWIRE) -- Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) a clinical stage biopharmaceutical company developing novel antibiotics to treat life-threatening...
Tetraphase Pharmaceuticals to Host Conference Call on March 8 to Discuss Fourth Quarter and Full Year 2016 Financial Results and Provide Corporate Update
March 03, 2017 08:00 ET
|
Tetraphase Pharmaceuticals
WATERTOWN, Mass., March 03, 2017 (GLOBE NEWSWIRE) -- Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a clinical stage biopharmaceutical company developing novel antibiotics to treat life-threatening...
Tetraphase Pharmaceuticals Doses First Patient in IGNITE3 Phase 3 Clinical Trial of Once-daily IV Eravacycline in cUTI
January 17, 2017 08:00 ET
|
Tetraphase Pharmaceuticals
WATERTOWN, Mass., Jan. 17, 2017 (GLOBE NEWSWIRE) -- Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) today announced dosing of the first patient in IGNITE3, the Company’s phase 3 clinical trial...